Overview

Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess safety and efficacy of two different doses of NV1FGF as compared to placebo. The secondary objective is to assess the pharmacokinetics of NV1FGF and FGF-1 protein.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi